Latest news

Read about the latest news and events here.

 
02. Jul. 2019, 17:43h

Introducing NanexTM multiSert+TM – the latest innovation from HOYA. A newly designed intraocular lens (IOL) delivered in a first-of-its kind preloaded delivery system

Singapore, 1 July 2019 – Today HOYA Surgical Optics, the worldwide leader in preloaded delivery systems, obtained CE Mark for NanexTM multiSert+TM.

A new level of protection
NanexTM multiSert+TM offers a very smooth surgical experience with outstanding delivery consistency. The 1.62mm injector tip of multiSert+TM is the world’s smallest nozzle size in an open-loop preloaded hydrophobic IOL system, designed for micro incision cataract surgery as low as 1.8mm. The newly designed NanexTM lens combines the proven material of over 10 million IOLs sold worldwide with the HOYA proprietary active oxygen processing treatment designed to reduce PCO.

Nanex™ Logo

 

In addition to offering the smallest nozzle size, multiSert+TM offers cataract surgeons multiple options for delivery. They have the option of using either a single-handed push or two-handed screw injection according to their surgical needs and personal preference. This offers a high level of flexibility and control. multiSert+TM also comes with a uniquely-designed insert shield for precise injector tip insertion depth management. It is a fully preloaded injector for consistent and predictable IOL delivery.

“I’m very proud to announce that HOYA Surgical Optics has obtained European CE Mark for NanexTM multiSert+TM. It is important to be continuously working to meet the needs of cataract surgeons and we believe expanding our portfolio with NanexTM will help us continue to do so” said John Goltermann Lassen, CEO of HOYA Surgical Optics.


Visit HOYA Surgical Optics booth #A115 at ESCRS

HOYA Surgical Optics will officially launch NanexTM multiSert+TM at the upcoming 37th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Paris, France. It will be available at booth #A115 at ESCRS from 14-18 September 2019. Surgeons are invited to visit the booth to find out more about HOYA’s latest products. NanexTM multiSert+TM is expected to be available to cataract surgeons in selected countries in September 2019.

About HOYA Surgical Optics
With more than 75 years of optical product expertise from the HOYA Group and over 30 years of experience in designing and producing intraocular lenses, HOYA Surgical Optics’ mission is to improve vision and quality of life for millions of people suffering from cataract.

Based on the core tenets of Quality, Trust, Dedication and Attention to Detail, HOYA Surgical Optics develops innovative and high-quality products that offer ease of use, safety and reliability to eye surgeons and ophthalmologists worldwide.

HOYA Surgical Optics is a division of HOYA Group.


About HOYA

Founded in 1941 in Tokyo, Japan, HOYA is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products.

HOYA is active in the fields of healthcare and information technology, providing intraocular lenses, eyeglasses, medical endoscopes, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs.

HOYA currently employs a multinational workforce of over 38,000 people across its 150 offices and subsidiaries worldwide.

 
13. Feb. 2019, 16:24h

HOYA Surgical Optics Welcomes New Vice President of Global Research & Development, Rakhi Jain

Singapore, 11 February 2019 - HOYA Surgical Optics (HSO), the world’s fastest growing IOL company and leader in preloaded delivery systems, has appointed Rakhi Jain, PhD as the Vice President Global Research & Development who will be based in the Singapore Global Headquarters office. She has the responsibility of leading global R&D operations across Singapore and Japan, as well as new product development and overall product portfolio management. Rakhi is a member of the Global Management Team at HSO and plays an integral role in helping to create differentiation through product design and innovation.

Rakhi has over 15 years of experience in the ophthalmic industry. Prior to joining HSO, Rakhi was the Senior Director of Implantable Design and Development at Alcon. Prior to Alcon, Rakhi’s experience include Senior Program Manager at PowerVision, Inc. and varying roles of increasing responsibility at Abbott Medical Optics Inc.  Rakhi earned her PhD in Biomedical Engineering from The Ohio State University in Columbus, Ohio, USA.  She obtained a Master’s degree in Biomedical Engineering from Drexel University in Philadelphia, Pennsylvania, and prior to that, graduated from John Hopkins University in Baltimore with a Bachelor’s of Science degree in Biomedical Engineering.

HSO New Vice President Rahki Jain

 


About HOYA Surgical Optics
With more than 75 years of optical product expertise from the HOYA Group and over 30 years of experience in designing and producing intraocular lenses (IOL), HOYA Surgical Optics’ mission is to improve vision and quality of life for millions of people suffering from cataract.
Based on the core tenets of Quality, Trust, Dedication and Attention to Detail, Hoya Surgical Optics develops innovative and high-quality products that offer ease of use, safety and reliability to eye surgeons and ophthalmologists worldwide. HOYA Surgical Optics is the fastest growing IOL company in the world and the global market leader in developing preloaded IOLs.
HOYA Surgical Optics is a division of HOYA Corporation.

 
22. Jan. 2019, 02:00h

HOYA Surgical Optics Completes Acquisition of Mid Labs and Fritz Ruck

Singapore, 22 January 2019 - HOYA Surgical Optics (“HSO”), the intraocular lens and related products division of HOYA Group, today announced that it has completed the acquisition of medical device companies Mid Labs and Fritz Ruck. Mid Labs is a California-based company focused on the research, innovation, development, engineering and manufacturing of ophthalmic medical surgical devices used to prevent blindness caused by certain retinal diseases and traumatic injuries. Fritz Ruck is based in Eschweiler, Germany, and manufactures dual function phacoemulsification machines and accessories as well distributes other ophthalmic devices and instruments.

This acquisition will help to broaden HOYA Surgical Optics’ product portfolio and enable HSO to better serve its customers’ broader needs for high quality ophthalmic products, equipment and services. Through this, HOYA Surgical Optics aims to accelerate the growth of IOL sales and further solidify its position as the fastest growing IOL company globally.

The acquisition also provides an opportunity for HOYA Surgical Optics to enter the global retinal market and continue its expansion beyond the current cataract market.  With the growing elderly population worldwide and the improving healthcare infrastructure in developing countries, retinal disease treatment is expected to grow at higher rates in the future. HOYA Surgical Optics will be able to leverage Mid Lab’s best-in-class vitrectomy cutters, machines and other vitreoretinal surgical products.
HOYA Surgical Optics announced a definitive agreement to acquire Mid Labs and Fritz Ruck on 18 October 2018.

Hoya Acquisition Image

 


About HOYA Surgical Optics
With more than 75 years of optical product expertise from the HOYA Group and over 30 years of experience in designing and producing intraocular lenses (IOL), HOYA Surgical Optics’ mission is to improve vision and quality of life for millions of people suffering from cataract.

Based on the core tenets of Quality, Trust, Dedication and Attention to Detail, Hoya Surgical Optics develops innovative and high-quality products that offer ease of use, safety and reliability to eye surgeons and ophthalmologists worldwide. HOYA Surgical Optics is the fastest growing IOL company in the world and the global market leader in developing preloaded IOLs.

HOYA Surgical Optics is a division of HOYA Group.

About HOYA

Founded in 1941 in Tokyo, Japan, HOYA is a global technology and med-tech company and a leading supplier of innovative high-tech and medical products.

HOYA is active in the fields of healthcare and information technology, providing intraocular lenses, eyeglasses, medical endoscopes, optical lenses as well as key components for semiconductor devices, LCD panels and HDDs.

HOYA currently employs a multinational workforce of over 38,000 people across its 150 offices and subsidiaries worldwide.


Media Contact:
Sandra Gulbicki
Global Communications Manager
HOYA Surgical Optics
sandra.gulbicki@hoya.com

 
15. Jan. 2019, 17:47h

A Human Model to Test Implants for Cataract Surgery

Researchers at the University of East Anglia in collaboration with Hoya Surgical Optics have improved a laboratory model that simulates cataract surgery on human donor eyes.

Their latest human model allows evaluation of artificial intraocular lens (IOL) implants under conditions that better reflect the post-surgical environment.

A cataract is a clouding of the eye’s lens and affects millions worldwide. At present, the only way of treating cataract is with surgery and it is estimated that by 2020, more than 30 million such operations will be performed annually.

During cataract surgery, the eye’s cloudy natural lens is removed and replaced with an IOL.

Initially, outcomes from cataract surgery are superb, but a haziness known as Posterior Capsule Opacification (PCO) can develop in a significant number of patients following surgery.

At the moment the only treatment for PCO is laser surgery - which is expensive and not without risks. There is therefore a need for better understanding the physiological events driving PCO and to better manage the condition.

The human capsular bag model was pioneered at UEA in the 1990s and has progressively evolved with time.

Lead researcher Prof Michael Wormstone, from UEA’s School of Biological Sciences, said: “Our model now mimics the transient nature of inflammation that patients experience after cataract surgery. It is more reflective of clinical events and allows comparative evaluation of different types of IOLs.

“We believe this latest model will allow assessment of current commercial IOLs and will aid the development of next generation lenses.”

The team used this clinically relevant model to assess the influence of two commercial market-leading IOLs (Alcon Acrysof™ and Hoya Vivinex™) on PCO management.

Their findings showed that cell growth on the posterior capsule was reduced, light-scatter in the central visual axis was found to be lower and growth on the IOL surface was significantly reduced with the Hoya Vivinex™ IOL relative to the Alcon Acrysof™.

The research team conclude that “our model system predicts that the Hoya Vivinex™ is better able to manage events leading to PCO than the Alcon Acrysof™ IOL”.

The research was funded by Hoya Surgical Optics and The Humane Research Trust.

‘An in vitro human lens capsular bag model adopting a graded culture regime to assess putative impact of IOLs on PCO formation’ is published in the journal Investigative Ophthalmology and Visual Science on January 10, 2019.

African Woman with glaucoma